{"prompt": "['HER2+ breast cancer assessed at the local laboratory prior to initiation of neoadjuvant therapy.', 'HER2+ status must be determined based on breast biopsy material obtained prior to neoadjuvant', 'treatment and is defined as 3+ by immunohistochemistry (IHC) and/or positive by HER2', 'amplification by in situ hybridization (ISH) with a ratio of 2 for the number of HER2 gene copies', 'to the number of chromosome 17 copies', 'Hormone receptor status of the primary tumour determined by local assessment. Hormone', 'receptor-positive status may be either positive (i.e. ER-positive and/or PgR-positive) or negative', '(i.e. ER-negative and PgR-negative)', 'Completed all neoadjuvant chemotherapy and surgery. Adjuvant radiotherapy may be planned or', 'ongoing at study entry and adjuvant hormone therapy is allowed during the study. Note that study', 'treatment cannot be initiated within < 2 weeks of surgery but must be initiated 9 weeks from the', 'last administration of systemic neoadjuvant therapy.', 'No evidence of residual, locally recurrent or metastatic disease after completion of surgery.', 'Patients with clinical suspicion of metastases must undergo radiological assessments per', 'institutional practice to rule out distant disease.', \"Wound healing after breast cancer surgery adequate per investigator's assessment to allow\", 'initiation of study treatment within < 9 weeks of last systemic neoadjuvant therapy', 'No adjuvant chemotherapy planned. Note that adjuvant hormonal treatment is allowed during the', 'study.', 'General criteria', 'Signed Informed Consent Form', 'Age 18 years at time of signing Informed Consent Form', \"Ability to comply with the study protocol, in the investigator's judgment\", 'Eastern Cooperative Oncology Group performance status 0 or 1', 'Intact skin at planned site of subcutaneous (SC) injections (thigh)', 'LVEF 55% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)', 'within 28 days of study randomization', 'No major surgical procedure unrelated to breast cancer within 28 days prior to randomization or', 'anticipation of the need for major surgery during the course of study treatment', 'For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual', 'intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as', 'defined below:', 'Women must remain abstinent or use non-hormonal contraceptive methods with a failure rate of', '<1% per year, or 2 effective non-hormonal contraceptive methods during the study treatment', 'periods and for 7 months after the last dose of study treatment. Women must refrain from', 'donating leggs during this same period.', 'A woman is considered to be of childbearing potential if she is post-menarchal, has not reached a', 'post-menopausal state (post-menopausal defined as 12 continuous months of amenorrhea with', 'no identified cause other than menopause), and has not undergone surgical sterilization (removal', 'of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment', 'with local guidelines or requirements.', 'Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year include', 'bilateral tubal ligation, male sterilization (with appropriate post-vasectomy documentation of the', 'absence of sperm in the ejaculate) and copper intrauterine devices.', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical', 'trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar,', 'ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods', 'of contraception.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '21 / Protocol MO40628, Version 12']['For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom,', 'and agreement to refrain from donating sperm, as defined below:', 'With female partners of childbearing potential or pregnant female partners, men must remain', 'abstinent or use a condom during the study treatment periods and for seven months after the last', 'dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm', 'during this same period.', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical', 'trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar,', 'ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods', 'of preventing drug exposure.', 'A negative serum pregnancy test must be available prior to randomization for women of', 'childbearing potential (defined as post-menarchal, has not had 12 continuous months of', 'amenorrhea with no identified cause other than menopause, and has not undergone surgical', 'sterilization [removal of ovaries and/or uterus])', 'Exclusion Criteria', 'Patients who meet any of the following criteria will be excluded from study entry:', 'Cancer-specific criteria', 'Stage IV (metastatic) breast cancer', 'Current or prior history of active malignancy (other than current breast cancer) within the last five', 'years. Appropriately treated non-melanoma skin cancer; in situ carcinomas, including cervix,', 'colon, or skin; or Stage I uterine cancer within the last five years are allowed.', 'A patient with previous invasive non-breast cancer is eligible provided he/she has been disease', 'free for more than five years.', 'Previous systemic therapy (including chemotherapy, immunotherapy, HER2-targeted agents,', 'endocrine therapy [selective oestrogen receptor modulators, aromatase inhibitors], and antitumor', 'vaccines) for treatment or prevention of breast cancer, except neoadjuvant Perjeta, Herceptin and', 'chemotherapy for current breast cancer', 'General criteria:', 'Investigational treatment within four weeks of enrolment', 'Serious cardiac illness or medical conditions including, but not confined to, the following:', '- History of NCI CTCAE v4.0 Grade 3 symptomatic congestive heart failure (CHF) or New', 'York Heart Association (NYHA) Class Il', '- High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate 100/min at rest,', 'significant ventricular arrhythmia [ventricular tachycardia], or higher-grade atrioventricular', '[AV]-block, such as second-degree AV-block Type 2 [Mobitz II] or third-degree AV-block)', '- Serious cardiac arrhythmia or severe conduction abnormality not controlled by adequate', 'medication', '- Angina pectoris requiring anti-angina medication', '-', 'Clinically significant valvular heart disease', '-', 'Evidence of transmural infarction on electrocardiogram (ECG)', '- Evidence of myocardial infarction within 12 months prior to randomization', '-', 'Poorly controlled hypertension (e.g., systolic > 180 mmHg or diastolic > 100 mmHg)', 'History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural', 'heart disease (e.g., severe left ventricular systolic dysfunction [LVSD], left ventricular', 'hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '22 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}